Baseline Feature of a Randomized Trial Assessing the Effects of Disease Management Programs for the Prevention of Recurrent Ischemic Stroke  by Fukuoka, Yasuko et al.
Baseline Feature of a Randomized Trial Assessing the Effects
of Disease Management Programs for the Prevention
of Recurrent Ischemic StrokeYasuko Fukuoka, RN, PHN, MSN,* Naohisa Hosomi, MD, PhD,†
Takeshi Hyakuta, RN, PhD,‡ Toyonori Omori, MD, MPH, PhD,x Yasuhiro Ito, MD, PhD,jj
Jyunichi Uemura, MD, PhD,{ Kazumi Kimura, MD, PhD,{
Masayasu Matsumoto, MD, PhD,† Michiko Moriyama, RN, PhD,#
and DMP Stroke Trial InvestigatorsFrom the *Division
Biomedical and Health S
†Department of Clinical
School of Biomedical an
Hiroshima; ‡Faculty of
College of Nursing, Hir
Nutrition, Tokyo; jjDepa
Hospital, Toyota; {Dep
Medical School Hospita
Science, Institute of Bio
University, Hiroshima, Ja
Received September 2
accepted October 16, 201
610Background:Comprehensive and long-term patient education programs designed to
improve self-management can help patients better manage their medical condition.
Using disease management programs (DMPs) that were created for each of the risk
factor according to clinical practice guidelines, we evaluate their influence on the
prevention of stroke recurrence. Methods: This is a randomized study conducted
with ischemic stroke patients within 1 year from their onset. Subjects in the
intervention group received a 6-month DMPs that included self-management
education provided by a nurse along with support in collaboration with the primary
care physician. Those in the usual care group received ordinary outpatient care.
The primary end points are stroke recurrence and stroke death. Patientswere enrolled
for 2 years with plans for a 2-year follow-up after the 6-month education period (total
of 30months).Results:A total of 321 eligible subjects (average age, 67.3 years; females,
96 [29.9%]), including 21 subjects (6.5%) with transient ischemic attack, were enrolled
in this study. Regarding risk factors for stroke, 260 subjects (81.0%) had hypertension,
249 subjects (77.6%) had dyslipidemia, 102 subjects (31.8%) had diabetes mellitus, 47
subjects (14.6%) had atrial fibrillation, and 98 subjects (30.5%) had chronic kidney dis-
ease. There were no significant differences between the 2 groups with respect to sub-
ject characteristics. Conclusions: This article describes the rationale, design, and
baseline features of a randomized controlled trial that aimed to assess the effects of
DMPs for the secondary prevention of stroke. Subject follow-up is in progress and
will end in 2015. Key Words: Stroke—disease management programs—self-
management—prevention of recurrence—primary care setting—risk factor control.
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BASELINE FEATURE OF DMP STROKE TRIAL 611Various types of clinical practice guidelines have
been created that offer high quality treatments. There
is a high probability that patients will reduce or
discontinue medications on their own, leading to a
high risk of stroke recurrence.1 The prevention of
ischemic stroke recurrence improves with meticulous
control of the associated risk factors. In addition,
many of the risk factors are associated with lifestyle
activities such improper diet, lack of exercise, smoking,
and overconsumption of alcohol. Adequate control of
risk factors is difficult without lifestyle adjustments.
In patients with coronary artery disease, it has been
shown that positive changes in lifestyle in combination
with medical therapy decrease the mortality rate.2
Patients and their families often do not have enough
information regarding risk factors for ischemic stroke
and the available methods of self-management.3
Comprehensive and long-term patient education
programs designed to improve self-management can
help patients better manage their medical condition in
a manner consistent with the guidelines while
addressing their individual risk factors.4
We used disease management programs (DMPs) aimed
at preventing the recurrence of ischemic stroke as a tool
for providing such education. DMPs lead to treatment
optimization, prevention of treatment-related complica-
tions, and reduced aggravation of physiologic and psy-
chologic conditions.5 DMPs have been shown to be
effective in preventing the deterioration of diseases and
in reducing increases in medical expenses.6,7 In this
DMP Stroke Trial, we used DMPs that were created
for each risk factor according to clinical practice
guidelines 4,8-12 to evaluate the efficacy of the program
in preventing stroke recurrence.
This article describes the rationale, design, and baseline
features of a randomized controlled trial aimed at assess-
ing the efficacy of DMPs facilitated by nurses in the pre-
vention of stroke recurrence.Methods
Trial Design
This is a multicenter, randomized (1:1), open-label,
parallel group study conducted in outpatients with a
prior history of stroke. The study protocol and
informed consent form were approved by the institu-
tional review board of each center. Written informed
consent for participation was obtained from each pa-
tient. In addition, this study is being conducted under
the health insurance system of Japan, in accordance
with the Declaration of Helsinki and the Ethical Guide-
lines on Clinical Studies of the Ministry of Health,
Labour and Welfare of Japan. This study is registe-
red under the following IDs: UMIN000007808 and
NCT02121327.Study Population
Between September 2010 and November 2012, we
enrolled patients between 40 and 80 years within 1 year
from the onset of ischemic stroke (including transient
ischemic attack [TIA]). The diagnosis of the stroke sub-
type was made by the physician as either atherothrom-
botic or cardioembolic or lacunar or other based on the
National Institute of Neurological Disorders and Stroke
criteria.13
Patients were excluded if they had severe complica-
tions or physical symptoms that would hinder their
ability to carry out the program content. These were
patients with modified Rankin Scale scores of 4 or more
at discharge or with dementia (scores of #20 of 30 on
the revised Hasegawa’s Dementia Scale14). However, if
a caregiving family member living with the patient could
support management, the patient was included even if
he/she had dementia. Patients were excluded if they
received medical care in a medical/nursing care facility.
Additionally, pregnant women and individuals under ter-
minal care were excluded.
Study Setting and Randomization
This study is a randomized controlled trial comparing
the intervention group, members of which underwent
DMPs conducted by nurses, and the usual care group,
members of which received conventional treatment
without DMPs. Because the recurrence rate differs
depending on the subtype of ischemic stroke,15 the
subjects were randomized to either the intervention or
the usual care group after being stratified by ischemic
stroke subtype.
Subsequently, with the objective to prevent recurrence
in ischemic stroke patients, the intervention group
received the 6-month DMPs. After completion of the
educational programs, the subjects are followed for
24 months for stroke recurrence monitoring over a total
of 30 months.
At the time of registration, information regarding the
subjects’ baseline characteristics and whether any person
was living with the subject was collected. The diagnostic
criteria for risk factors were as follows: for hypertension,
those who were taking antihypertensives or had a blood
pressure of 140/90 mm Hg or more8; for diabetes
mellitus, those who were taking antidiabetic medications
and/or insulin or had a glycated hemoglobin level of
6.5% or more10; for dyslipidemia, those who were taking
hypolipidemics, had high-density lipoprotein cholesterol
less than 40 mg/dL, low-density lipoprotein cholesterol
140 mg/dL or more, or triglyceride 150 mg/dL or more9;
for chronic kidney disease, those with an estimated
glomerular filtration rate less than 60 mL/minute/
1.73 m2 (calculated from gender, age, and serum
creatinine)11; for smoking, those with a current smoking
habit (ie, those who smoked within 1 month of
Table 1. Study outcomes
Outcomes Evaluation
Primary outcomes
Stroke recurrence rate and death due to stroke
Secondary outcomes
Economic indicators Unplanned consultation and days of hospitalization in conjunction with ischemic
stroke and risk factors
Physiologic indicators Framingham risk score-general cardiovascular disease 10-year risk, body weight,
body mass index, blood pressure, total cholesterol, HDL cholesterol, LDL
cholesterol, triglycerides, serum creatinine, blood urea nitrogen, HbA1c, blood
glucose, PT-INR (only as necessary)
Psychologic indicators Self-efficacy scale of health behavior in patients with chronic disease, CES-D, SF-36
Evaluation of self-monitoring and
lifestyle improvement actions
Evaluated subject frequency of checking blood pressure, taking medicine, following
the prescribed diet, and exercising (0, never; 1, once a month; 2, once a week; 3,
2-3 times a week; 4, 4-5 times a week; 5, every day). The quantity and frequency
of alcohol intake and smoking
Abbreviations: CES-D, Center for Epidemiologic Depression Scale; HbA1c, glycated hemoglobin; HDL, high-density lipoprotein; LDL, low-
density lipoprotein; PT-INR, prothrombin time international ratio; SF-36, 36-item short form.
Y. FUKUOKA ET AL.612enrollment); and for excessive drinking, those who
consumed 46 g of pure ethanol or more every day.
Regarding psychologic indicators, the self-efficacy
scale on health behavior in patients with chronic
disease,16 the Center for Epidemiologic Depression
Scale,17 and the Medical Outcomes Study 36-item short
form18 were evaluated at enrollment and were either
completed on-site or collected by mail.
Primary and Secondary Outcomes
The primary end points of this study are recurrence rate
and mortality from stroke. The secondary end points
include an improvement in the indicators listed in
Table 1 (eg, economic, physiologic, and psychologic indi-cators and evaluation of self-monitoring and lifestyle
improvement).
DMP for the Intervention Group
The intervention was performed based on the scheme
shown in Figure 1. The program objectives were helping
the subject to acquire skills for self-management and the
control of ischemic stroke risk factors. The duration of
the education program in this study was 6 months,
which is the minimum duration required for behavior
modification.19
The subjects were educated via interviews and phone
calls (Fig 2). Interviews were conducted a total of 4 times:
twice between registration and the first month ofFigure 1. Scheme illustrating the interven-
tion.
Figure 2. Disease management program outline. Abbreviations: CES-D, Center for Epidemiologic Depression Scale; SF-36, 36-item short form.
BASELINE FEATURE OF DMP STROKE TRIAL 613intervention, once at month 3, and once at month 6 in the
subject’s home or a collaborating medical facility. Phone
calls were made a total of 10 times every 2 weeks.
The intervention supported for self-management and
drug therapy to control subject’s risk factors using 14
types of education booklets created by the researchers
as well as a self-management record notebook in which
the subject recorded daily blood pressure, body weight,
and lifestyle improvement goals (in Appendix). The edu-
cation booklets used were selected such that they were
suitable for the individual subject.
Nurses worked collaboratively with patients and their
physicians to achieve individualized clinical target valuesand self-management goals (Table 2). Abnormalities in
self-monitored values or data or the development or
exacerbation of subjective symptoms were reported
immediately to the primary care physician. Appropriate
treatment and therapeutic activities were assessed
collaboratively by the nurses and primary care
physicians and were based on the clinical practice
guidelines.
The details of the intervention are Figure 2.
Education for the Usual Care Group
At the initial interview, the subjects were given
instructions using a leaflet that consisted of material
Table 2. Goals of risk factor control and self-management
Management goals Target value
Hypertension Systolic blood pressure
Diastolic blood pressure
Under 140 mm Hg
Under 90 mm Hg
Dyslipidemia HDL cholesterol
LDL cholesterol
Triglycerides
Over 40 mg/dL
Under 140 mg/dL
Under 150 mg/dL
Diabetes mellitus HbA1c Under 6.5%
Management goals Performance objectives
Blood pressure measurement Measure twice daily (in the morning within 30 min of awakening and in the
evening at bedtime)
Body weight measurement Measure once daily
Medication Comply as prescribed
Diet Proper calories 5 Patient’s ideal body weight (patient BMI 22 kg/m2) 3 degree
of activity (light, 20; heavy, 30)
Upper limit of calories: 2000 kcal, salt intake: #6 g/d
Proper amount of protein intake (in case of chronic kidney disease)
Exercise Over 30 min a day, every day if possible, or 180 min a week
Smoking Smoking cessation
Alcohol intake Amount of alcohol per day is no more than 20 g of pure alcohol
Abbreviations: BMI, body mass index; HbA1c, glycated hemoglobin; HDL, high-density lipoprotein; LDL, low-density lipoprotein.
To convert values for LDL cholesterol to millimoles per liter, multiply by .02586; for HDL cholesterol, multiply by .02586; and for triglyc-
eride, multiply by .01129. BMI is the weight in kilograms divided by the square of the height in meters.
Y. FUKUOKA ET AL.614extracted from the educational booklets. They also
received a self-management record notebook, as
described previously. Otherwise, the patients were
given routine medical consultations as per standard
practice.Quality Assurance
Each of the 14 types of booklets (in Appendix) used in
the present study covered the contents of the patient’s
education, according to the self-management and lifestyle
recommendations of each of the clinical practice guide-
lines for stroke4 and the risk factors.8-12 The content was
created based on discussions with neurologists, chronic
disease nurse specialists, and registered dieticians.
To ensure quality, the intervention protocol was created
such that 22 research nurses who possessed the
knowledge and techniques needed for patient education
could administer the intervention. Before the intervention,
the research nurses were also given information on the
various methods used to control ischemic stroke and
the risk factors and received training on the different
techniques used in disease management. During the
intervention, they conducted twice-monthly conferences
to strategies about subject’s problems with nurses who
specialized in chronic disease and stroke. Treatments
were assessed based on the clinical practice
guidelines.4,8-12 The nurses also received advice from
neurologists or diabetologists as necessary.Data Collection Schedule
To investigate the effect of the program on outcomes,
the subjects are followed for 2 years after properly
adhering to the program (30 months from enrollment).
Primary outcome and economic indicators are assessed
every 3 months in both groups. Data on stroke recurrence
or death caused by stroke are also confirmed. Further-
more, responses to the self-efficacy, quality of life, and
depression scales as well as blood pressure, body weight,
and blood test results are collected every 6 months.Sample Size
Based on an annual 10% recurrence rate of stroke
(including TIAs) in the usual care group,15 a 60% risk
reduction rate in the intervention group,20 and 2.5 years
of follow-up, the number of subjects required to detect
differences between the intervention group and the
usual care group was calculated to be 136 for each group
(2-tailed 5% significance level, power level of 80%).
Assuming that 10% of the subjects would be lost to
follow-up, the sample size was set at 152 for each group
and 304 for the 2 groups combined.Statistical Analysis
The intent-to-treat analysis is used to compare the
outcomes of the intervention and usual care group. To
ensure the comparability of randomized samples, all
BASELINE FEATURE OF DMP STROKE TRIAL 615baseline indicators at the time of registration were
analyzed. The data are expressed as the mean6 standard
deviation or median (minimum-maximum) for the
continuous variables and as frequencies and percentages
for the discrete variables. The differences in continuous
variables between the groups were examined using
the t test or Mann–Whitney U test. The differences in
categorical variables between the groups were examined
using the c2 test.
For the primary end point, the cumulative incidence of
events is estimated using the Kaplan–Meier method. The
cumulative incidence curves for the 2 groups are
compared using a log-rank test. The Cox proportional
hazard model is also used to estimate the relative risk
(hazard ratio) and the 95% confidence interval, adjusting
for confounding factors, in which risk reduction is ex-
pressed as (12hazard ratio) 3 100%.
For the secondary end point analysis of compliance
with the guidelines, the number of subjects with a systolic
blood pressure 140mmHg ormore,8 low-density lipopro-
tein cholesterol of 140 mg/dL or more,9 and glycated
hemoglobin of 6.5% or more10 are calculated everyTable 3. Baseline characteris
Characteristics Interventio
Characteristics
Females, n (%) 5
Unemployed, n (%) 10
Marital status: married, n (%) 12
Living with another person, n (%) 13
Average age, mean 6 SD, y 67
Subject profile
Recurrent stroke history, n (%) 3
Modified Rankin Scale score, median (min-max)
Time to registration from onset, mean 6 SD, d 1
Hypertension, n (%) 13
Diabetes mellitus, n (%) 5
Dyslipidemia, n (%) 12
Atrial fibrillation, n (%) 2
Chronic kidney disease, n (%) 5
Alcohol intake, n (%) 1
Smoking, n (%) 2
Subtype, n (%)
Atherothrombotic 4
Cardioembolic 2
Lacunar 5
Other 1
Transient ischemic attack 1
Treatment regimen, n (%)
Antiplatelets 11
Anticoagulants 3
Antihypertensives 10
Hypolipidemics 8
Antidiabetics 3
Abbreviation: SD, standard deviation.6 months in each group and compared with a c2 test.
Every 6 months data are analyzed with an analysis of
covariance using baseline data as covariates for the phys-
iologic indicators. The psychologic indicators and the
extent to which self-monitoring and lifestyle improve-
ment activities were implemented are analyzed with a
Mann–Whitney U test.Results
Of the 562 subjects who met the criteria, 321 consented
to participate in the study (consent rate, 57.1%). The sub-
jects were randomly assigned to the intervention group
(n5156) or the usual care group (n 5 165).
The demographic data and subject profile of each
group are shown in Table 3. The mean age was 67.3 6
8.5 years, and 16.8% of the subjects had a past history of
stroke. The number of subjects who exhibited primary
risk factors of ischemic stroke were as follows: 260 sub-
jects (81.0%) had hypertension, 102 subjects (31.8%) had
diabetes mellitus, 249 subjects (77.6%) had dyslipidemia,
47 subjects (14.6%) had atrial fibrillation, and 98 subjectstics and subject profiles
n group, N 5 156 Usual care group, N 5 165 P value
0 (32.1) 46 (27.9) .465
6 (67.9) 115 (69.7) .810
8 (82.1) 131 (79.4) .574
4 (85.9) 137 (83.0) .539
.1 6 7.6 67.5 6 9.3 .684
0 (19.2) 24 (14.5) .297
0 (0-3) 0 (0-3) .952
09 6 87 117 6 84 .406
1 (84.0) 129 (78.2) .202
1 (32.7) 51 (30.9) .811
4 (79.5) 125 (75.8) .503
6 (16.7) 21 (12.7) .346
0 (32.1) 48 (29.1) .628
2 (7.7) 18 (5.6) .146
4 (15.7) 36 (22.0) .196
9 (31.4) 48 (29.1) .809
3 (14.7) 19 (11.5)
5 (35.3) 67 (40.6)
8 (11.5) 21 (12.7)
1 (7.1) 10 (6.1)
8 (75.6) 118 (71.5) .402
1 (19.9) 34 (20.6) .870
8 (69.2) 103 (62.4) .199
4 (53.8) 79 (47.9) .285
4 (21.8) 33 (20.0) .875
Y. FUKUOKA ET AL.616(30.5%) had chronic kidney disease. The disease subtypes
were as follows: atherothrombotic (n 5 97, 30.2%), cardi-
oembolic (n 5 42, 13.1%), lacunar (n 5 122, 38.0%), other
ischemic stroke (n 5 39, 12.1%), and TIA (n 5 21, 6.5%).
No statistically significant differences in the indicators
were observed. There were no differences between the 2
groups with respect to subject disability as evaluated by
modified Rankin Scale (Table 3).
The medications taken by the subjects were as follows:
antiplatelets (n 5 236, 73.5%), anticoagulants (n 5 65,
20.2%), antihypertensives (n5 211, 65.7%), hypolipidemics
(n 5 163, 50.8%), and antidiabetics (n 5 67, 20.9%). There
were no significant differences in the use of any of these
drugs between the 2 groups.Discussion
The aim of this study is to evaluate the efficacy of DMPs
in preventing recurrent stroke. Patient enrollment was
closed at the end of November 2012, and follow-up
studies are ongoing. This article describes the study ratio-
nale and design as well as the subjects’ baseline features.
Depending on their recovery status andwhether they are
in the acute, recovery, or maintenance (living) phase of
management, ischemic stroke patients often do not stay in
the same medical institution where they undergo their
initial consultation. For this reason,maintainingcontinuous
support for patient education and long-term self-manage-
ment is difficult. Patient education in medical clinics in
Japan is primarily performed by physician, which places a
large burden on physicians and may result in inadequate
patient education. Therefore, this intervention scheme
both supports physicians’ practice and improves patient
outcomes.
Because ischemic stroke has multiple divergent risk
factors, we designed a comprehensive (as opposed to a
single intervention) approach to control these factors.
The aim of the program is for patients to gain knowledge
and to learn techniques that they can use. DMPs strategy
also incorporated behavior modification theories19,21 such
as methods to improve self-efficacy and depression. It
may be possible to investigate the intervention process
of recurrence prevention based on the behavior
modification theory.
The limitations of the present study include the small
sample size and the fact that the study could not be
blinded. There was no way to blind the study because
the group assignments had to be explained to patients
when describing the study, and the educational interven-
tion involved additional interaction with nurses that the
usual care group did not receive. The sample size of this
study was calculated based on a 60% risk reduction of
ischemic stroke recurrence with DMPs. It was determined
from a previous study evaluating a nurse-directed multi-
disciplinary intervention for congestive heart failure
with a 56% decrease in readmission.20 And, a strokerecurrence rate in the first year was approximately 5% in
the Japanese stroke centers and 12.8% in the Japanese
community-based observational study.15,22 Therefore, we
assumed that 60% reduction rate would be possible
providing disease managements programs to the
patients followed-up in the nonstroke center hospitals or
clinics. In the present study, 52.3% of enrolled patients
are under follow-up in the nonstroke center hospitals or
clinics.
The low recruitment rate (57.1%) is another limitation
of this study that may have led to selection bias. Some
patients did not consent even when they were informed
at recruitment of the presence of risk factors and of the
fact that control of these risk factors influenced recur-
rence. This indicates that the number of patients who un-
derstand that recurrence prevention is important in
ischemic stroke and that prevention is achieved through
controlling risk factors are limited.
To reduce the number of patients with recurrent
ischemic stroke, it is essential that patients understand
the importance not only of rehabilitation but also of
controlling risk factors. Our consent rate is similar to
that reported in other studies of stroke.23,24 We
convinced that it is of great importance to thoroughly
investigate the efficacy of DMPs for preventing stroke
recurrence.Conclusion
This article describes the rationale, design, and baseline
features of a randomized controlled trial aimed at assess-
ing the efficacy of DMPs in the prevention of recurrent
ischemic stroke. Patient enrollment is closed, and
follow-up studies are in progress. The results derived
from this study could establish the potential usefulness
of DMPs for the secondary prevention of ischemic stroke
in a primary care setting.
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